Evidence map›Paper›PMID 27121720›Full record

ArticleCancer research and treatment2017

Use of a High-Throughput Genotyping Platform (OncoMap) for

Dalyong Kim, Yong Sang Hong, Jeong Eun Kim, Kyu-Pyo Kim, Jae-Lyun Lee, Sung-Min Chun, Jihun Kim, Se Jin Jang, Tae Won Kim

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research and treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Dalyong KimDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Yong Sang HongDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Jeong Eun KimDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Kyu-Pyo KimDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Jae-Lyun LeeDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Sung-Min ChunDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Jihun KimDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Se Jin JangDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Tae Won KimDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Ulsan College · KRUniversity of Ulsan · KRAsan Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCetuximab demonstrates improved efficacy outcomes in patients with metastatic colorectal cancer (mCRC) harboring wild-type MATERIALS AND

methodsExtended

resultsThe OncoMap detected 57 additional mutations (25.1%): 25 (11%) in

conclusionSanger sequencing is not sufficient for selecting candidates for cetuximab treatment. High-throughput extended

Indexed as

DNA Mutational AnalysisMutationAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsCetuximabColorectal NeoplasmsDrug Resistance, NeoplasmExonsFemaleHigh-Throughput Nucleotide SequencingHumansKaplan-Meier EstimateMiddle AgedNeoplasm GradingNeoplasm MetastasisNeoplasm StagingAntineoplastic Agents, ImmunologicalCetuximabKRAS protein, humanProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)CetuximabColorectal neoplasmsHigh-throughput nucleotide sequencingRAS genes

Identifiers

PMID27121720
PMCPMC5266405
OpenAlexW2342918528

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.